Cancer and Molecular Therapies

Prof. Ronit Satchi-Fainaro

Nanomedicine

Major efforts invested into the development of new drugs often fail to be translated into meaningful clinical benefit for cancer patients Developing effective novel therapeutics for cancer while accurately predicting their clinical success in certain cancer types remains an urgent unmet medical need. Prof. Satchi-Fainaro incorporates cutting edge multidisciplinary basic, translational and clinical approaches to explore this scientific “blind spot”. To this end, Satchi-Fainaro develops clinically relevant 3D cancer models that better capture the clinical characteristics and drug https://satchifainarolab.com/ responsiveness of human cancer. These models are being exploited for the development of efficacious clinically-translatable therapies for various cancer types. Her vision is that this multidisciplinary approach will revolutionize our perception of tumor progression and consequently the way we diagnose and treat cancer.

Prof. Satchi-Fainaro is at Department of Physiology and Pharmacology, where she is head of the Cancer Research & Nanomedicine Laboratory, Head of the TAU Kahn 3D BioPrinting Initiative and holds the Kurt and Herman Lion Chair in Nanosciences and Nanotechnologies. She completed her PhD in Polymer Chemistry and Cancer Nanomedicine at the University of London and her postdoctoral training at Harvard University and Children’s Hospital Boston working on Vascular and Cancer Biology. She was awarded the Fulbright, Rothschild, and JULUDAN Prizes, Teva Pharmaceutical Industries Founders Award, the 2019 Youdim Family Prize for Excellence in Cancer Research, 2020 Kadar Family Award for Outstanding Research, the 2020 Humboldt Foundation Bessel Research Prize, and “Woman of the Year” by Globes magazine. She serves on the Board of Directors of Teva Pharmaceutical Industries Ltd.